Trasicor in acute supraventricular arrhythmias (Hebrew)

The effectiveness of oxyprenolol hydrochloride (Trasicor) was evaluated in 40 episodes of supraventricular arrhythmias in 36 patients. The drug was given iv in doses of up to 10 mg (1 mg/min) and was found to be safe and effective in 21 episodes in 19 patients without underlying heart disease. In 12 episodes sinus rhythm was restored and in five other episodes the ventricular rate was significantly decreased. However, in 19 episodes in 17 patients in whom the supraventricular arrhythmia was a manifestation of underlying heart disease, the results were less satisfactory. Sinus rhythm was restored in only five such episodes and in six additional episodes the ventricular response was significantly decreased. Side effects, mainly decreases in blood pressure, occurred mostly in the latter group of patients.